Survival After Surgery for Pathologic Stage IA　Non-Small Cell Lung Cancer Associated With　Idiopathic Pulmonary Fibrosis by 齋藤 雄一
  
 
 
 
 
学位論文 
 
Survival After Surgery for Pathologic Stage IA Non-Small Cell  
Lung Cancer Associated With Idiopathic Pulmonary Fibrosis  
（病理病期 IA 期特発性肺線維症合併非小細胞肺癌に対する外科治療の成績） 
 
 
 
 
 
 
 
 
 
ＤＭ１００１８ 齋藤 雄一 
 
 
 
 
 
 
 
 
 
 
北里大学大学院医療系研究科医学専攻博士課程 
臨床医科学群 呼吸器外科学 
指導教授 佐藤 之俊 
 著者の宣言 
 
  本学位論文は、著者の責任において実験を遂行し、得られた真実の結果に 
基づいて正確に作成したものに相違ないことをここに宣言する。 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
－ ii － 
 病理病期 IA期特発性肺線維症合併非小細胞肺癌に対する外科
治療の成績 
 
はじめに 
 我が国における肺癌の死亡者数は年々増加傾向を示しており、日本における癌死のうち
最も死亡数が多いのが肺癌である。肺癌の死亡数は男性では 1993年に胃癌を抜いて一位、
1998年には男女併せた死亡数でも一位となっている。肺癌の危険因子としての特発性間質
性肺炎は臨床的に周知の事実であるが、実際に日本や英国における特発性間質性肺炎のフ
ォローアップ研究では、4-15%の症例に肺癌の発生が認められたと報告されている。肺癌
と特発性間質性肺炎の間には何らかの因果関係があると想定されており、ただ単に発生原
因を共有しているだけなのか、それとも線維化肺が癌の発生母地であるのか未だ結論付け
られていない。いずれにせよ、この 2 つの疾患の合併は常に念頭において診療しなければ
ならなく、長期経過観察中の間質性肺炎患者に置いては注意深い肺癌スクリーニングが重
要である。さらに、肺癌に対する治療の観点からは特発性間質性肺炎を合併していること
は、治療に大きな制約をもたらすことが知られている。すなわち、手術、放射線、化学療
法などにより特発性間質性肺炎の悪化がもたらされる場合があるために、通常のガイドラ
インに沿った治療が行えない場合があるのである。私も臨床医として、特発性間質性肺炎
による肺機能低下が存在するために肺癌治療を断念せざるを得なかった症例を何回か経験
してきた。実地臨床の場では、治療による根治あるいは延命が可能であるのか、それとも
best supportive careによる延命効果の方が高いのか、確たる evidenceのない状況下で臨
床判断を迫られる事を多々経験してきた。そこで私は根治の可能性の高い早期肺癌に注目
し、特発性間質性肺炎の合併群と非合併群の 2 群を比較して、その外科治療成績を明らか
にする研究を行うこととした。 
方法 
病理病期 IA 期非小細胞肺癌 350 例を研究対象とした。特発性間質性肺炎の診断は 
The International Consensus Statement of the American Thoracic Society and the 
European Respiratory Society による定義に基づいて行った。膠原病や職業性暴露や環境
曝露歴、薬剤吸入歴のある症例は除外した。 
結果 
350 全例が病理病期 IA期の非小細胞肺癌外科切除例であり、そのうち 28 例に特発性間質
性肺炎の合併を認めた。術後 5 年生存率は全体で 85.4%、合併群で 54.2%、非合併群で 
88.3%であった（p < 0.0001）。単変量解析の結果、p < 0.01 を示した要因は年齢、性別、
喫煙指数、縮小手術、腺癌と 特発性間質性肺炎合併の有無であった。これらの要因で多変 
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量解析を行ってみると特発性間質性肺炎合併のみが予後不良因子であった。2 群間の症例
数の偏りを補正するために Propensity Score-Matching 解析を行った。非合併群 322 例中
から性別、年齢、喫煙指数、肺機能、血液ガスデータ、術式、手術時間、出血量、腫瘍径、
腺癌を合併群と matchingさせて 28 例を抽出し 2群間比較を行った。その結果において
も 5年生存率は合併群で有位に低く、単変量・多変量解析では腺癌と特発性間質性肺炎合
併が予後不良因子であった。 
考察 
早期肺癌は手術療法の適応であるが、特発性間質性肺炎が合併している場合には慎重な
検討が必要である。今回の検討では特発性間質性肺炎を合併した場合、54.2%と 5 年生存
率が著しく低値であることが初めて明らかとなった。単変量・多変量解析の結果は特発性
間質性肺炎が予後不良因子であり、Propensity Score-Matching 解析の結果も同様であっ
た。 
結語 
特発性間質性肺炎を合併した病理病期 IA期非小細胞肺癌外科切除例の術後5年生存率は
54.2%であり、外科治療によって半数以上の患者が 5 年後も生存していることが初めて明
らかとなった。化学療法と放射線治療が特発性間質性肺炎を悪化させることを考慮すると、
外科治療は積極的に検討するに値すると考えられた。 
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Survival After Surgery for Pathologic Stage IA Non-Small Cell Lung 
Cancer Associated With Idiopathic Pulmonary Fibrosis 
 
 
1. Abstract 
 
Many problems exist in regard to the treatment of lung cancer patients with idiopathic 
pulmonary ﬁbrosis (IPF), but few reported studies have investigated the long term 
prognosis after pulmonary resection in such patients. The purpose of the present study was 
to determine the postoperative survival of patients with pathologic stage IA non-small cell 
lung cancer (NSCLC) and IPF. We retrospectively reviewed 350 patients with pathologic 
stage IA NSCLC who underwent pulmonary resections at our institution between 
September 1994 and December 2007. We analyzed and compared 28 of these patients, who 
had simultaneous lung cancer and IPF, with the remaining 322 lung cancer patients 
without IPF. The 5-year survival rates were 54.2% in pathologic stage IA lung cancer 
patients with IPF and 88.3% in those without IPF (p < 0.0001). Univariate analyses showed 
that age, sex, Brinkman Index, limited resection, operation time, adenocarcinoma, and IPF 
were signiﬁcant prognostic factors for survival (p < 0.10). By multivariate analysis, however, 
only IPF was a signiﬁcant prognostic factor for survival (p = 0.007). Propensity 
score-matching analysis conﬁrmed that only IPF was signiﬁcant prognostic factor (p = 
0.043). The 5-year survival rate of patients with pathologic stage IA NSCLC and IPF is 
54.2%. IPF has independent, adverse effects on survival of pathologic stage IA NSCLC 
patients treated with pulmonary resection 
 
Key words: Idiopathic pulmonary fibrosis, Non-small cell lung cancer, survival 
 
 
2. Introduction 
 
Idiopathic pulmonary ﬁbrosis (IPF) is the most common subset of the idiopathic 
interstitial pneumonias and has the worst prognosis, resulting in a median survival of 2.5 
to 3.5 years [1]. Among patients with IPF, the cause of death is not only the disease itself 
but also ischemic heart disease, lung cancer, or pneumonia. One recent population-based 
analysis in the United States showed that 60% of the deaths caused by IPF were due to 
pulmonary ﬁbrosis, 2.9% to lung cancer, 2.4% to pneumonia, 2.2% to ischemic heart disease, 
and 1.3% to cerebrovascular disease [2].  
Thoracic surgeons often face difﬁculties in treating patients who have IPF along with 
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lung cancer because of poor prognosis of IPF itself and the high mortality rate after 
pulmonary resection [3–6]. Oncologists or radiologists also have similar difﬁculties because 
chemotherapy or radiotherapy, or both, can possibly cause the development of IPF, 
including acute respiratory deterioration, termed acute exacerbation [7]. Although many 
problems exist in regard to the treatment of lung cancer patients with IPF, few studies have 
investigated the long-term prognosis of pulmonary resection, especially in early stage lung 
cancer patients with IPF. In this retrospective study, we attempted to clarify the outcome of 
pulmonary resection in pathologic stage IA non-small cell lung cancer (NSCLC) patients 
with IPF and to evaluate the signiﬁcance of surgical intervention in these patients. 
 
3. Materials and methods 
 
3-1. Patients 
The Saitama Cardiovascular and Respiratory Center and the Thoracic Surgery 
databases were queried, and records of 350 patients who underwent surgical resection for 
pathological stage IA NSCLC from September 1994 to December 2007 were selected. Of 
these patients, 28 (8.0%) had primary lung cancer concomitant with IPF and comprised the 
IPF patient group in this study. They were compared with the remaining 322 lung cancer 
patients without IPF. The institutional review boards did not require the patients’ approval 
or informed consent for retrospective review of their records and images because 
individuals were not identiﬁed within the study.  
 
3-2. Diagnosis of IPF 
The radiographic ﬁndings of preoperative chest conventional or high-resolution 
computed tomography (CT) studies of all patients were reevaluated to conﬁrm the presence 
of pulmonary ﬁbrosis. The diagnosis of IPF was deﬁned according to the International 
Consensus Statement of the American Thoracic Society and the European Respiratory 
Society [1]. Histopathologic examinations used several sections of resected noncancerous 
lung and included a suitable lesion if the ﬁnding of pulmonary ﬁbrosis was detected on 
preoperative CT. Patients with surgical pathology of incidental usual interstitial 
pneumonia, but who had no pulmonary ﬁbrosis on preoperative radiographic imaging, were 
included in the non-IPF patient group.  
 
3-3. Definition of complications 
Acute exacerbation of IPF was deﬁned as [8] (1) increased respiratory distress; (2) 
ﬁbrosis, newly developed ground glass opacity, and inﬁltrative shadow on chest 
roentgenogram; (3) decline in resting partial pressure of arterial oxygen of more than 10 
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mm Hg; and (4) absence of heart failure or infectious lung disease. Pneumonia was 
diagnosed by the presence of new or progressive pulmonary inﬁltrates, or both, on the chest 
roentgenogram plus two or more of the following criteria: (1) fever (38°C); (2) leukocytosis 
(12  10 9 /L); (3) purulent sputum; or (4) isolation of pathogen in respiratory secretions. 
Air leakage was deﬁned as prolonged if it lasted for more than 7 days. Heart failure was 
diagnosed by an abnormal result on the echocardiogram, levels of B-natriuretic peptide 
that exceeded normal reference ranges, or by a clinical evaluation.  
 
3-4. Exclusion criteria of IPF patient group 
Exclusion criteria for the IPF patient group were the clinical evidence of 
connective tissue disease, signiﬁcant occupational or environmental exposure to hazardous 
agents, and exposure to harmful drugs. No patients with a resting partial pressure of 
arterial oxygen of less than 60 mm Hg were included because they are excluded from 
undergoing general anesthesia and surgery at our institution. As a result, patients with 
severely symptomatic IPF were usually judged inoperable, and almost all patients with IPF 
were symptomless (subclinical IPF).  
 
3-5. TNM classification and surgery 
All patients had pathologic stage IA primary lung cancer based on the T N M 
classiﬁcation of the International Union Against Cancer [9] and had undergone procedures 
other than a lobectomy, such as bilobectomy, segmentectomy, or wedge resection. A limited 
operation, deﬁned as wedge resection or segmentectomy, was performed for patients with 
poor pulmonary function. Mediastinal nodal dissection was routinely used in lobectomy, but 
not in a limited operation.  
 
3-6. Oxygen inhalation 
Oxygen inhalation was administered at minimal level to maintain oxygen 
saturation at 92% or greater for IPF patients as far as was possible.  
 
3-7. Perioperative treatment 
No patients in this study received preoperative chemotherapy or radiotherapy and 
no patients received perioperative steroid or acetylcysteine inhalation. If acute 
exacerbation of IPF occurred, steroid pulse therapy with methylprednisolone (1 or 2 g per 
day for 3 or 4 days as one course) was used.  
 
3-8. Follow-up after discharge 
After discharge from the hospital, patients were regularly monitored at 1 to 6 
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months, unless there was tumor recurrence or the patient had any health problems. CT, 
magnetic resonance imaging, or bone scintigraphy was used to evaluate any abnormalities, 
but asymptomatic patients did not routinely undergo bone scans or brain examinations.  
 
3-9. Cancer-related death 
Cancer-related death is defined as death by recurrence, and cause of death due to 
respiratory failure to include pneumonia, acute exacerbation, or chronic pulmonary 
insufﬁciency.  
 
3-10. Brinkman Index 
The Brinkman Index (BI) was scored as the number of cigarettes smoked/day 
multiplied by the number of years since smoking started [10]. 
 
3-11. Statistical Analysis 
Categoric data are expressed as counts and proportions and were compared by 
using the Chi-square test or Fisher exact test to assess differences. Survival rates were 
calculated by the Kaplan-Meier method, and univariate analyses were performed by 
log-rank test. Multivariate analyses were performed by means of the Cox proportional 
hazards model with SPSS 19.0 software (IBM, Somers, NY) on variables with a value of p < 
0.10 in univariate analyses. A value of p < 0.05 was treated as signiﬁcant.  
 
3-12. Propensity Score-Matching Analysis 
A propensity score-matched analysis was performed to get a well-balanced 
comparison between the patients with and without IPF. The propensity scores were 
generated using multilogistic analysis. The IPF group vs non-IPF group was used as the 
dependent variable, and the 15 characteristics in Table 1 were entered as covariates. Using 
a greedy matching protocol, which is a 1:1 matching algorithm with no replacements [11], 
we matched a non-IPF patient with an IPF patient by matching propensity scores without 
clinical information on prognosis. Matched pairs were eliminated from the algorithm and 
not eligible for subsequent matching. We were able to match 28 non-IPF patients (8.70% of 
the non-IPF patients) with 28 IPF patients who had similar propensity score. 
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4. Results 
 
4-1. Characteristics 
There were 350 patients who met the entry criteria for this study, comprising 28 
with IPF and 322 without IPF. Lung cancers with IPF were found more frequently in men 
(85.7%) and in patients aged older than 70 years (46.4%). Patient characteristics are 
reported in Table 1. Age, BI, resting partial pressure of arterial carbon dioxide, tumor size, 
and the percentage of men and squamous cell carcinomas were signiﬁcantly higher in the 
lung cancer patients with IPF than in those without IPF.  
 
4-2. Survival rates 
Survival data were collected for each patient from the date of the operation, 
with a median duration of follow-up of 4.8 years (range, 0 to 15.7 years). The 5-year 
actuarial survival rate for the entire group was 85.4%. The 5-year survival rate of 
patients with IPF (54.2%) was lower than that of patients without IPF (88.3%), and the 
difference in survival rates between the two groups was signiﬁcant (p < 0.0001; Fig. 1). 
 
Univariate and multivariate analyses  
Signiﬁcant differences in overall survival were demonstrated with age (p = 0.001), 
sex (p = 0.001), BI (p = 0.003), limited operation (p = 0.023), adenocarcinoma (p =0.005), and 
IPF (p < 0.0001). Use of the variables with a value of p < 0.10 from the univariate analysis 
in a subsequent multivariate analysis revealed that only IPF was a signiﬁcant prognostic 
factor for survival (Table 2). 
 
Morbidity and mortality 
Morbidity and mortality rates are listed in Table 3. Postoperative morbidity rates 
were 40.7% for patients with IPF vs 18.8% for patients without IPF (p = 0.007). The 30-day 
mortality rate in patients both with and without IPF was 0%; however, patients with IPF 
showed a 3.6% rate of 90-day mortality vs 0.3% for those without IPF (p =0.028). An acute 
exacerbation of IPF developed in 3 patients (10.7%). None these patients died within 30 
days of resection, but 1 patient died on of acute exacerbation of IPF postoperative day 70. 
 
Causes of death 
During the follow-up period, 42 patients (12.0%) died, and the most common cause 
was cancer-related death; 17 patients (4.9%) died of recurrent lung cancer (Table 4). The 
rates of cancer-related death were 17.9% for patients with IPF and 3.7% for patients 
without IPF (p = 0.001). Deaths due to respiratory failure occurred in 14.3% of patients 
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with IPF and in 1.2% of those without IPF (p <0.0001). Of the 4 patients with IPF who died 
of respiratory failure, two died of exacerbation of IPF over 90 days postoperatively. One 
patient died of aspiration pneumonia on postoperative day 128, and the other patient died 
of gradual progression of IPF at 1595 days. 
 
Propensity score-matching analysis 
We performed propensity score-matching analysis to reduce selection bias 
according to the sample size between patients with IPF and without IPF. Through this 
method, 28 patients were selected in the non-IPF group and showed similar characteristics 
(sex, age, BI, pulmonary function, blood gas data, surgical procedure, operation time, blood 
loss, T factor, and adenocarcinoma) as the IPF group (Table 5). Lower-lobe lung cancer was 
observed in 50.0% of IPF patients compared with 21.4% in non-IPF patients (p = 0.026). An 
analysis of the 5-year survival rate and the risk of death showed a rate of 54.2% for patients 
with IPF, which was signiﬁcantly lower than that of patients without IPF (p = 0.038; Fig 2). 
A multivariate analysis using adenocarcinoma (p = 0.091) and IPF (p = 0.049), the two 
variables that were deemed signiﬁcant from a univariate analysis, demonstrated a 
signiﬁcant association between overall survival and IPF (Table 6). 
 
5. Discussion 
 
Serious morbidity and a poor prognosis are common after IPF patients undergo 
pulmonary resection [5, 12–18] which make surgical treatment challenging in such 
patients. Because surgical indications for early lung cancer are usually considered to be 
good, it is very important to know the 5-year survival rate, a standard measure of the 
effectiveness of lung cancer treatment, of IPF patients with early-stage lung cancer 
after surgical treatment.  
Recently, Watanabe and colleagues [5] reported a 5-year survival rate of 61.6% 
after pulmonary resection in lung cancer patients with IPF, including pathologic stages 
IA and IB. However, Fujimoto and colleagues [12] reported extremely poor prognosis 
and a 5-year survival rate of 0% for patients with IPF. Both studies comprised few 
patients, so we do not know with certainty whether surgical resection will improve the 
prognosis of early-stage lung cancer in patients with IPF.  
In the present study, the 5-year survival rate was 54.2% after pulmonary 
resection in pathological stage IA NSCLC patients with IPF. Our results also indicate 
that IPF had a signiﬁcant negative effect on survival after surgical resection among 
these patients, because the multivariate Cox proportional hazards model showed IPF 
was the only signiﬁcant independent factor for prognosis after surgical treatment 
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among these patients. However, we do not believe these data indicate that the presence 
of IPF with early-stage lung cancer is an absolute contraindication to performing 
surgical resection, as indicated by the 54.2% survival rate at 5 years; rather, such 
patients must be evaluated case-by-case. Importantly, these ﬁndings imply that it may 
be necessary for thoracic surgeons to evaluate surgical risk factors more carefully, even 
in cases of early-stage lung cancer. Our data may help to explain to lung cancer 
patients the potential difﬁculties of surgical treatment and the prospective prognosis.  
High morbidity and mortality rates after pulmonary resection have been 
reported in patients with IPF [5, 13–15, 17]. The IPF patients in our study had 
signiﬁcantly higher postoperative morbidity and mortality rates than those without 
IPF (Table 5). The 28 patients with IPF had a 10.7% incidence of postoperative 
exacerbation of IPF. The exacerbation of IPF was acute in 3 patients: 2 recovered and 
were discharged from hospital, and the other died during hospitalization. Although the 
small number of patients with IPF precluded an evaluation of risk factors for the 
incidence of acute exacerbation, this incidence rate is similar to that reported in the 
8.7% to 70.0% of patients with IPF after other anticancer treatments [7, 18–23]. The 
present study documented a signiﬁcant difference between the two groups in the 
frequency of pulmonary complications (p = 0.001); however, there was no signiﬁcant 
difference after propensity score matching (p = 0.567). These data may suggest that it 
was difﬁcult to further reduce the frequency of pulmonary complications, even if we 
had selected patients with subclinical IPF to tolerate pulmonary resection.  
The rate of cancer-related death in our series was higher in patients with IPF 
than without IPF before propensity score matching, but the difference after propensity 
score matching was not signiﬁcant (Table 6). The higher risk of death after pulmonary 
resection in these patients could be related to factors unrelated to the cancer, because 
many patients with IPF died of respiratory failure, both before and after propensity 
score matching.  
The present study has some limitations: First, most patients with IPF in this 
study had subclinical IPF and were selected preoperatively to have pulmonary function 
adequate to undergo surgical treatment. In fact, the patients with IPF had similar 
pulmonary function test results as those without IPF. Therefore, postoperative survival 
of patients with many symptoms of IPF would be expected to be worse than that of our 
patients. Second, there could be a bias in the location of lung tumors between patients 
with and without IPF, although we found no signiﬁcant differences between the two 
groups. If a patient with interstitial pneumonia under goes an upper lobectomy, the 
disease, which has a predilection for the basal lung segments, might be difﬁcult to 
diagnose. However, if we miss patients with IPF who have a tumor in the upper or 
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middle lobe of the lung, the true postoperative survival rate of patients with IPF would 
not be expected to be better than 54.2%. Third, this is a retrospective, single-institution 
study, and the sample size was limited. To conﬁrm these observations, prospective 
studies that include a larger series of patients are required.  
In conclusion, IPF has independent, adverse effects on survival of pathologic 
stage IA NSCLC patients treated with pulmonary resection, as evidenced by a 5-year 
survival rate of 54.2% after resection. Although this result indicates that surgical 
treatment for early-stage lung cancer might not be contraindicated, patients with stage 
IA NSCLC concomitant with IPF should be carefully selected and should have good 
respiratory function. 
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7. Figure legends 
 
Figure 1. Overall 5-year survival in patients with pathologic stage IA non-small cell lung 
cancer 
Overall 5-year survival in patients with pathologic stage IA non-small cell lung cancer was 
54.2% for the 28 patients with idiopathic pulmonary fibrosis (IPF, dashed line) and 83.6% 
for the 322 patients without IPF (solid line). The median follow-up was 4.20 years for IPF 
patients and 4.95 years for non-IPF patients. 
 
Figure 2. Overall 5-year survival in 28 patients, matched by propensity score, with 
pathologic stage IA non-small cell lung cancer 
Propensity score-matching analysis resulted in 54.2% of overall 5-year survival in 28 
patients with both pathologic stage IA non-small cell lung cancer and idiopathic pulmonary 
fibrosis, simultaneously (IPF, dashed line), while it was 82.6% for the 322 patients without 
IPF (solid line). The median follow-up was 4.20 years for IPF patients and 4.15 years for 
non-IPF patients group. 
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8. Figures 
 
Figure 1 
 
 
Figure 2 
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9. Tables 
 
Table 1. Patients Characteristics 
 
       Non-IPF 
Characteristicsa   IPF Group  Group p Valueb 
 
Patients, No.    28 (8.0) 322 (92.0)  
Age, years         70.4 ± 6.54 64.5 ± 10.9  0.005 
Sex, female    4 (14.3) 176 (54.7)  0.001 
Brinkman Index   863 ± 383 522 ± 689  0.010 
Vital capacity, liters   3.07 ± 0.69 3.20 ±1.87  0.711 
Vital capacity, %   87.1 ± 15.5 93.1 ± 16.2  0.062 
FEV1, liter    2.24 ± 0.61 2.24 ± 0.66  0.977 
FEV1, %    73.5 ± 8.67 72.9 ± 13.9  0.843 
PaO2, mmHg    81.9 ± 10.3 85.8 ± 11.7  0.103 
PaCO2, mmHg    39.2 ± 4.96 42.0 ± 3.48 <0.001 
Lower lobe    14 (50.0) 113 (35.1)  0.116 
Limited operation   5 (17.9) 60 (18.6)  0.919 
Operation time, min   171 ± 55.9 169 ± 64.2  0.910 
Blood loss, mL    156 ± 156 155 ± 156  0.984 
T factor, T1b    11 (39.3) 102 (31.7)  0.429 
Adenocarcinoma   7 (25.0) 258 (80.1) <0.001 
Squamous cell carcinoma  19 (67.9) 43 (13.4) <0.001 
 
aCategoric data are expressed as number (%), and continuous data as mean ± 
standard deviation. bValue of p < 0.05 are significant. 
 
FEV1 = forced expiratory volume in 1 second; IPF = idiopathic pulmonary 
fibrosis; PaCO2 = partial pressure of carbon dioxide in arterial blood; PaO2 = 
partial pressure of oxygen in arterial blood. 
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Table 2. Results of Multivariate Analysis of Preoperative Prognostic 
Factors Influencing Survival in Pathologic IA Non-Small Cell Lung 
Cancer Patients 
 
Variable      HR (95% CI)   p Valueb 
 
Age, years    1.037 (0.996-1.080)   0.080 
Sex, male    2.165 (0.778-6.026)   0.139 
Brinkman Index   1.000 (1.000-1.001)   0.359 
Limited operation   1.261 (0.562-2.826)   0.574 
Operation time   0.997 (0.991-1.003)   0.257 
Adenocarcinoma   0.922 (0.424-2.005)   0.837 
IPF     3.113 (1.373-7.058)   0.007 
 
aValue of p < 0.05 are significant. 
 
CI = confidence interval; HR = hazard ratio; IPF = idiopathic pulmonary 
fibrosis. 
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Table 3. Postoperative Morbidity and Mortality 
 
       Non-IPF 
     IPF Group  Group  
Variable    No. (%)  No. (%)  p Valuea 
 
Morbidity    11 (40.7) 60 (18.8)  0.007 
Acute exacerbation        3 (10.7) 0 (0)  <0.0001 
Pulmonary complications  10 (35.7) 41 (12.7)  0.001 
 Pneumonia   3 (10.7) 5 (1.6)   0.002 
 Prolonged air leakage  6 (21.4) 27 (8.4)  0.023 
 Others    1 (3.6)  11 (3.4)   0.965 
Cardiac complications   3 (10.7) 20 (6.2)  0.356 
 Heart failure   1 (3.6)  5 (1.6)   0.430 
 Arrhythmia   2 (7.1)  16 (5.0)  0.617 
 Others    2 (7.1)  15 (4.7)  0.557 
Mortality 
 30-day    0 (0)  0 (0) 
 90-day    1 (3.6)  1 (0.3)   0.028 
 
aValue of p < 0.05 are significant. 
IPF = idiopathic pulmonary fibrosis. 
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Table 4. Causes of Death 
 
       Non-IPF 
     IPF Group  Group  
Cause     No. (%)  No. (%)  p Valuea 
 
Cancer-related death   5 (17.9) 12 (3.7)  0.001 
Respiratory failure        4 (14.3) 4 (1.2)  <0.0001 
Others     3 (10.7) 14 (4.3)  0.133 
 
aValue of p < 0.05 are significant. 
IPF = idiopathic pulmonary fibrosis. 
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Table 5. Patients Characteristics Matched by Propensity Score 
 
       Non-IPF 
Characteristicsa   IPF Group  Group p Valueb 
 
Patients, No.       28     28  
Age, years         70.4 ± 6.54 70.2 ± 7.66  0.911 
Sex, female    4 (14.3) 7 (25.0)  0.313 
Brinkman Index   863 ± 383 968 ± 954  0.595 
Vital capacity, liters   3.07 ± 0.69 2.87 ±0.85  0.343 
Vital capacity, %   87.1 ± 15.5 83.5 ± 17.4  0.419 
FEV1, liter    2.24 ± 0.61 2.07 ± 0.64  0.314 
FEV1, %    73.5 ± 8.67 74.3 ± 13.1  0.794 
PaO2, mmHg    81.9 ± 10.3 87.3 ± 13.1  0.103 
PaCO2, mmHg    39.2 ± 4.96 39.8 ± 2.86  0.577 
Lower lobe    14 (50.0) 6 (21.4)  0.026 
Limited operation   5 (17.9) 5 (17.9)  >0.99 
Operation time, min   171 ± 55.9 194 ± 88.8  0.272 
Blood loss, mL    156 ± 156 168 ± 212  0.806 
T factor, T1b    11 (39.3) 8 (28.6)  0.397 
Adenocarcinoma   7 (25.0) 7 (25.0)  >0.99 
Squamous cell carcinoma  19 (67.9) 13 (46.4)  0.105 
 
aCategoric data are expressed as number (%), and continuous data as mean ± 
standard deviation. bValue of p < 0.05 are significant. 
 
FEV1 = forced expiratory volume in 1 second; IPF = idiopathic pulmonary 
fibrosis; PaCO2 = partial pressure of carbon dioxide in arterial blood; PaO2 = 
partial pressure of oxygen in arterial blood. 
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Table 6. Multivariate Analysis of Preoperative Prognostic Factors 
Influencing Survival in Pathologic IA Non-Small Cell Lung Cancer 
Patients Matched by Propensity Score 
 
Variable      HR (95% CI)   p Valueb 
 
Adenocarcinoma   0.393 (0.141-1.100)   0.075 
IPF     0.311 (0.100-0.965)   0.043 
 
aValue of p < 0.05 are significant. 
 
CI = confidence interval; HR = hazard ratio; IPF = idiopathic pulmonary 
fibrosis. 
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